IP Library › Granted Patent US 12,194,294
Granted Patent B2
US 12,194,294 · App. 16/775,515 · Granted Jan 14, 2025

Oral drug delivery devices and methods using iontophoresis

Inventors: Amrita Banerjee (Fargo, ND); Renwei Chen (Santa Barbara, CA); Shamsul Arafin (Goleta, CA); Samir Mitragotri (Lexington, MA)
Assignees: The Regents of the University of California; President and Fellows of Harvard College
A61N1/325A61N1/0509A61N1/0548
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,194,294
App. No.
16/775,515
Granted
Jan 14, 2025
Kind
B2
Abstract

Disclosed herein are methods, systems, and devices for oral drug delivery. The method generally involves orally administering a drug delivery device to the subject in need of treatment and triggering iontophoresis. The drug delivery device includes one or more active agents for delivery to the subject. The method can include the step of delivering the active agent to the intestinal mucosa after iontophoresis is triggered at the site, or simultaneously as iontophoresis is applied at the site. After the active agent(s) are delivered, the drug delivery device can be released from the intestinal mucosa. The iontophoresis can be performed for a period of time and at an electrical current that is effective to improve permeability of the one or more active agents across the intestine compared to orally administering the same drug delivery device in the absence of iontophoresis.

Claims (29)

1. A method for oral drug delivery of an active agent to a subject in need thereof comprising:

a) orally administering an iontophoretic drug delivery device to the subject, wherein the iontophoretic drug delivery device comprises:

at least one electrode in direct contact with an outer surface of the iontophoretic drug delivery device or connected to the iontophoretic drug delivery device by an electrically conductive material,

a drug reservoir comprising the active agent, and

a mucoadhesive patch attached to or comprising the drug reservoir; and

b) providing iontophoresis at an electrical current in a range from 20 to 60 μA from the at least one electrode after orally administering the iontophoretic drug delivery device.

2. The method of claim 1 , wherein the drug delivery device provides iontophoresis after being triggered by an environmental stimulus, a timer, or a remote control.

3. The method of claim 2 , wherein at least two electrodes attach to a wall of the intestine, following step (a).

4. The method of claim 2 , wherein the active agent is released concurrently with the iontophoresis.

5. The method of claim 2 , wherein the iontophoresis is provided or performed in one or more cycles of iontophoresis.

6. The method of claim 5 , wherein a cycle comprises delivering electrical current for a period of time ranging from 0.5 to 20 minutes followed by a recovery time period ranging from 0.5 to 20 minutes.

7. The method of claim 2 , wherein iontophoresis is provided for longer than 30 minutes and less than 24 hours.

8. The method of claim 1 , wherein following step (a), the drug delivery device adheres to the intestinal mucosa.

9. The method of claim 1 , wherein a biocompatible protective coating is released from the drug delivery device to uncover the electrodes prior to providing iontophoresis.

10. The method of claim 9 , wherein the biocompatible protective coating is an enteric coating that dissolves or degrades before or upon reaching the intestine.

11. The method of claim 1 , wherein the active agent is a small molecule or macromolecule.

12. The method of claim 1 , wherein the subject has type 1 or type 2 diabetes and the active agent is insulin or an analog thereof.

13. The method of claim 12 , wherein the active agent is administered in an effective amount to reduce blood glucose levels.

14. The method of claim 1 , wherein the active agent is administered or present in the device at a dosage of from 1 U/kg to 100 U/kg.

15. A system for oral drug delivery of an active agent to a subject in need thereof comprising:

a) an intestinal iontophoretic device comprising:

a capsule;

at least two electrodes in direct contact with the outer surface of the capsule or connected to the capsule by an electrically conductive material; and

inside the capsule:

a mucoadhesive patch, and

an active agent;

b) a control unit in electrical communication with the electrodes of the intestinal iontophoretic device configured to provide an electrical current in a range from 20 to 60 μA.

16. The system of claim 15 , wherein the capsule comprises an outer enteric biocompatible protective coating.

17. The system of claim 15 , further comprising an active agent release trigger in or on the capsule.

Assignments (3)
CONFIRMATORY LICENSE Recorded Oct 12, 2022
From: UNIVERISTY OF CALIFORNIA SANTA BARBARA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 061656/0268 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2020
From: MITRAGOTRI, SAMIR
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 052775/0976 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2020
From: ARAFIN, SHAMSUL; BANERJEE, AMRITA; CHEN, RENWEI
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ON BEHALF OF ITS SANTA BARBARA CAMPUS
Reel/Frame 052776/0279 →
Continuity (2)
Provisional Application 62798373 · Jan 29, 2019
Related Publication 20200238081A1 · Jul 30, 2020
References Cited (35)
US 20020183686A1 · Darvish · 2002 [cited by examiner]
US 20050058701A1 · Gross · 2005 [cited by examiner]
US 20080188837A1 · Belsky · 2008 [cited by examiner]
US 20130337022A1 · Pillay · 2013 [cited by examiner]
WO WO2018213600A1 · 2018 [cited by examiner]
Alkilani et al. “Transdermal drug delivery: innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum.” Pharmaceutics 7(4): 438-470 (2015). [cited by applicant]
Brown et al. “Dermal and transdermal drug delivery systems: current and future prospects.” Drug Delivery 13(3): 175-187 (2006). [cited by applicant]
Chaturvedula et al. “In vivo iontophoretic delivery and pharmacokinetics of salmon calcitonin.” International Journal of Pharmaceutics 297(1-2): 190-196 (2005). [cited by applicant]
Chen et al. “Iontophoresis-driven penetration of nanovesicles through microneedle-induced skin microchannels for enhancing transdermal delivery of insulin.” Journal of Controlled Release 139(1): 63-72 (2009). [cited by applicant]
Chen et al. “Short-duration ocular iontophoresis of ionizable aciclovir prodrugs: A new approach to treat herpes simplex infections in the anterior and posterior segments of the eye.” International Journal of Pharmaceut… [cited by applicant]
Dixit et al. “Iontophoresis—an approach for controlled drug delivery: a review.” Current Drug Delivery 4(1): 1-10 (2007). [cited by applicant]
Dubey et al. “Electrically-assisted delivery of an anionic protein across intact skin: cathodal iontophoresis of biologically active ribonuclease T1.” Journal of Controlled Release 152(3): 356-362 (2011). [cited by applicant]
Gaillard-Bigot et al. “Vascular effects of treprostinil cutaneous iontophoresis on the leg, finger, and foot.” The Journal of Clinical Pharmacology 57(9): 1215-1220 (2017). [cited by applicant]
Green. “Iontophoretic delivery of peptide drugs.” Journal of Controlled Release 41(1-2): 33-48 (1996). [cited by applicant]
Huang et al. “Transdermal iontophoretic delivery of thyrotropin-releasing hormone across excised rabbit pinna skin.” Drug Development and Industrial Pharmacy 22(11): 1075-1081 (1996). [cited by applicant]
Jacoby et al. “Vaginal iontophoresis of a choline compound.” American Journal of Obstetrics and Gynecology 44(2): 250-258 (1942). [cited by applicant]
Kalia et al. “Iontophoretic drug delivery.” Advanced Drug Delivery Reviews 56(5): 619-658 (2004). [cited by applicant]
Kalluri et al. “Transdermal delivery of proteins.” Aaps Pharmscitech 12(1): 431-441 (2011). [cited by applicant]
Korsten et al. “Delivery of neostigmine and glycopyrrolate by iontophoresis: a nonrandomized study in individuals with spinal cord injury.” Spinal Cord 56(3): 212-217 (2018). [cited by applicant]
Lee et al. “MEMS devices for drug delivery.” Advanced Drug Delivery Reviews 128: 132-147 (2018). [cited by applicant]
Leonard et al. “Evaluation of the Caco-2 monolayer as a model epithelium for iontophoretic transport.” Pharmaceutical Research 17(10): 1181-1188 (2000). [cited by applicant]
Leonard et al. “Iontophoresis-enhanced absorptive flux of polar molecules across intestinal tissue in vitro.” Pharmaceutical Research 17(4): 476-478 (2000). [cited by applicant]
Martanto et al. “Transdermal delivery of insulin using microneedles in vivo.” Pharmaceutical Research 21(6): 947-952 (2004). [cited by applicant]
Mitragotri. “Current status and future prospects of needle-free liquid jet injectors.” Nature Reviews Drug Discovery 5(7): 543-548 (2006). [cited by applicant]
Myles et al. “Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral ontophoresis.” Advanced Drug Delivery Reviews 57(14): 2063-2079 (2005). [cited by applicant]
Pan et al. “The enhancing effect of electroporation and iontophoresis on the permeation of insulin through human skin.” Yao Xue Xue Bao= Acta Pharmaceutica Sinica 37(8): 649-652 (2002) [English Abstract]. [cited by applicant]
Pillai et al. “Transdermal iontophoresis of insulin: IV. Influence of chemical enhancers.” International Journal of Pharmaceutics 269(1): 109-120 (2004). [cited by applicant]
Ren et al. “Characterization of cornified oral mucosa for iontophoretically enhanced delivery of chlorhexidine.” European Journal of Pharmaceutics and Biopharmaceutics 99: 35-44 (2016). [cited by applicant]
Shoeibi et al. “Iontophoresis in ophthalmology: A review of the literature.” Reviews in Clinical Medicine 1(4): 183-188 (2014). [cited by applicant]
Tokumoto et al. “Effect of electroporation and pH on the iontophoretic transdermal delivery of human insulin.” International Journal of Pharmaceutics 326(1-2): 13-19 (2006). [cited by applicant]
Traverso et al. “Microneedles for drug delivery via the gastrointestinal tract.” Journal of Pharmaceutical Sciences 104(2): 362-367 (2015). [cited by applicant]
Kitian et al. “A novel remote controlled capsule for site-specific drug delivery in human GI tract.” International Journal of Pharmaceutics 382(1-2): 160-164 (2009). [cited by applicant]
Zhang et al. “Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applicaitons.” Clinical Pharmacokinetics 41(9): 661-680 (2002). [cited by applicant]
Zhang, et al. “A flexible device for ocular iontophoretic drug delivery.” Biomicrofluidics 10(1): 011911 (2016). [cited by applicant]
Zhuang et al. “A MEMS-based electronic capsule for time controlled drug delivery in the alimentary canal.” Sensors and Actuators A: Physical 169(1): 211-216 (2011). [cited by applicant]